Structure Modeling of the Norepinephrine Transporter by Góral, Izabella et al.
biomolecules
Article
Structure Modeling of the
Norepinephrine Transporter
Izabella Góral, Kamil Łątka and Marek Bajda *
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Abstract: The norepinephrine transporter (NET) is one of the monoamine transporters. Its X-ray
crystal structure has not been obtained yet. Inhibitors of human NET (hNET) play a major role in the
treatment of many central and peripheral nervous system diseases. In this study, we focused on the
spatial structure of a NET constructed by homology modeling on Drosophila melanogaster dopamine
transporter templates. We further examined molecular construction of primary binding pocket (S1)
together with secondary binding site (S2) and extracellular loop 4 (EL4). The next stage involved
docking of transporter inhibitors: Reboxetine, duloxetine, desipramine, and other commonly used
drugs. The procedure revealed the molecular orientation of residues and disclosed ones that are
the most important for ligand binding: Phenylalanine F72, aspartic acid D75, tyrosine Y152, and
phenylalanine F317. Aspartic acid D75 plays a key role in recognition of the basic amino group
present in monoamine transporter inhibitors and substrates. The study also presents a comparison of
hNET models with other related proteins, which could provide new insights into their interaction
with therapeutics and aid future development of novel bioactive compounds.
Keywords: norepinephrine transporter; homology modeling; ligand docking; reuptake inhibitors
1. Introduction
The norepinephrine transporter (NET) belongs to the family of sodium-coupled ion-dependent
transporters (SLC6). In high density NET occurs in the plasma membranes of noradrenergic neurons
and also in glial cells [1]. It is physiologically responsible for norepinephrine (NE) transport from the
synaptic cleft into presynaptic neurons [2]. The family of Na+ dependent transporters consists of many
proteins and includes i.e., transporters of amino acids, such as leucine transporter (LeuT) and biogenic
amine reuptake proteins, such as dopamine (DAT) and serotonin (SERT) transporters. All of these
share a resemblance in amino acid sequences, 3D protein structures, and transport mechanisms for
their substrates [3]. Transport by all neurotransmitter sodium symporters (NSSs) depends on Na+/K+
ATPase which maintains the concentration gradient of Na+ ions at both sides of the cell membrane [4].
This electrochemical potential is a driving force for translocation of one molecule of the substrate along
with sodium and other ions, which results in intracellular accumulation of neurotransmitter [3]. NET
and DAT are responsible for transport of each norepinephrine or dopamine molecule with one or two
sodium and one chloride ions. The SERT co-transports molecule of serotonin (5-HT) with one Na+ and
Cl− ions, while in the opposite direction a single potassium K+ ion is moved [5].
By regulating the concentration of released norepinephrine in the synaptic cleft, NET protein plays
a critical role in many central and peripheral mechanisms, such as cardiovascular effects or behavioral
processes. Blockage of NET has proven useful in the treatment of a variety of central nervous system
(CNS) disorders, such as attention deficit hyperactivity disorder (ADHD), panic and suicidal disorders,
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or depression [2]. The activity of NET can be modulated by both biogenic substrates and selective
or nonselective inhibitors of monoamine transporters. However, molecular mechanisms involved
in the action of this protein are still not fully understood [6]. Crystal structures of the transporters
may be useful in understanding the processes which they mediate. The Protein Data Bank provides
X-ray structures of the leucine transporter aLeuT (Aquifex aeolicus LeuT) and monoamine transporters
(MATs): dDAT (Drosophila DAT) and hSERT (human SERT) crystallized in 2005, 2013, and 2016 [7–10].
The human NET (hNET) crystal structure has not been obtained yet. The molecular structure of the
norepinephrine transporter is important for understanding the interactions with its ligands and future
development of more active and/or selective compounds. Isolated complementary DNA (cDNA),
which encodes the human noradrenergic transporter protein, provided the first information about this
structure and revealed that hNET comprises 617 amino acid residues [11,12]. The first significant data
about the tertiary structure and functioning of proteins from the SLC6 family came from studies on
prokaryotic homolog LeuT received from the bacterium Aquifex aeolicus [7]. Analysis of its sequence
and X-ray crystal structure revealed 20–25% overall homology with others where ~60% homology has
been demonstrated for the core region [9]. Experimental data have confirmed that other human MATs
consist of 620 (human DAT, hDAT) and 630 (hSERT) residues and also present high conservation of
topological domains whereas the main differences can be found at carboxy terminus [12]. Like all of
the monoamine transporters, NET also consists of 12 α-helical transmembrane spanning domains (TM)
with N- and C-termini located at the intracellular side. The primary substrate binding region (S1) occurs
between TM1, TM3, TM6, and TM8 [13]. Differences between prokaryotic and eukaryotic members
are marked in terms of the extensivity of N- and C-termini and the prolonged extracellular loop 2
(EL2) with a characteristic disulfide bond located between TM3 and TM4. Mammalian equivalents
also possess phosphorylation sites and post-translational modifications not present at prokaryotic
transporters [14,15]. A series of recombinant chimeric transporters, combining features of NET and
DAT, have turned out to be helpful in the identification of particular structure determinants engaged
in the ligand binding and substrate transport processes. The highest degree of conservation has
been observed at the first three transmembrane domains, which also coincides with other family
members of Na+/Cl− dependent transporters. Therefore, involvement of these three domains in
ion-dependence and uptake process is common at all related transporters. The same observations
have been found for TM5 to 8, where the chimeras combining NET and DAT caused loss of ability to
transport substrates [11,16]. Differences in pharmacological and kinetic profiles between NET and DAT
proteins led to the observation that the appreciable carboxy-terminal region derived from TM9 might
be responsible for the specific affinity of substrates and stereoselectivity which has been proposed as
typical of NET. Moreover, mutations at TM9 are connected with attenuated surface expression and
cause orthostatic intolerance [17]. Some characteristic determinants occurring within TM5–8 have been
proposed for high affinity binding of tricyclic antidepressants [16]. Mutagenesis studies within TM2
and intracellular loop 1 (IL1), including GXXXRXG motif, pointed this region as involved in regulating
the affinity of substrate and inhibitors [18,19]. Also, histidine residues placed at the terminal part of
EL2 are important for nisoxetine binding [20]. Mutations within EL3 have a much greater impact due to
the change in the architecture of connected TM5 and TM6, as a consequence of affecting the permeation
ability between TM1 and TM6 of noradrenaline and inhibition by desipramine [21]. To get a better view
into the structures of the transporter, the mechanism of alternating access and its influence on substrate
availability should been mentioned. The general principle of action is to allow for access to the ligand
binding site in protein from only one (external or internal) side but never from both at the same time.
This process prevents any loss of energy, related to uncontrolled movement of ions. The substrate
binds to the outward-faced conformation of the transporter. When the binding site is occupied, the
external gate closes and internal gate opens. After release of ions and the coupled neurotransmitter to
the intracellular space, the internal gate closes. The last part of this mechanism is connected with facing
the transporter outward and then the whole cycle is repeated. At the molecular level, translocation
of substrate is related to conformational changes of protein first observed at prokaryotic homolog
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LeuT [1]. This mechanism differs to a certain extent at mammalian equivalents. Core domains represent
coordinated hinge movement. In the first step, TM1b and TM6a with extracellular loop 4 (EL4) bend
together and allow for penetration to the interior of the transporter. Differences can be found in the
movement of the domains located near the cell interior. In prokaryotic homologs, TM1a and TM6b are
kept together around the binding site region at a tilt of 25◦ [22]. While at MATs, the release of substrate
to the cytosol is possible because of the outward directed movement of mainly one core domain, i.e.,
TM1a, and inward movement of EL4 [4]. The mechanism of alternating access to the binding site of
prokaryotic LeuT may be explained by the “rocking bundle” hypothesis [22]. The hNET and hDAT are
thought to operate by the following stoichiometry: NE/Na+/Cl− 1:1:1 for hNET and DA/Na+/Cl− 1:2:1
for hDAT. Both of these result in positive charge transfer during the transport cycle [23]. Binding of the
inhibitors with the transporters is strictly dependent on Na+ ions [24]. LeuT X-ray structure resolved
the positions of amino acids at the binding site responsible for coupling sodium ions and determining
their features. Residues located in TM 1b and 6a and 7 formed a Na1 site, which is a supplement of
the binding pocket, hence making it accessible for substrates. Binding of the Na+ ion at the Na1 site
derived movement of the transporter toward outward-face, while the presence of an Na+ at the Na2
site caused opposite conformational changes [21]. A second cation binding site could be found closer
to the intracellular region between TM 1a and 8. During coordination of Na+ ion, amino acids residues
stitched two domains together, thereby stabilizing them closed from cytoplasmic site conformation.
Transition from outward to occluded protein state was triggered by the coordinated action of a substrate
with an active site and sodium ion binding to an Na2 site [25]. This mechanism was also supported by
molecular dynamics stimulations which revealed that unbinding of Na+ from an Na2 site leads to
unbinding of substrate molecule [21]. In comparison to other SLC6 members, LeuT represented Cl−
independent transport. A single chloride ion was coupled to the EL2 located 24.7 Å away from the
important Na1 site. Absence of an anion site in close relation to the binding pocket might explain why
Cl− was not involved in substrate translocation [26]. Positions of sodium ions at 4m48 dDAT crystal
structure coincided exactly with both Na sites in LeuT. The chloride ion was located adjacent to the Na1
ion which is consistent with findings from mutational study on chloride-dependent LeuT mutant [25].
Herein, we decided to address some essential questions, regarding to the lack of the X-ray crystal
structure of human NET and unknown molecular details underlying the mechanism of action for
already approved drugs. We wanted to present and discuss molecular details of the spatial architecture
of the hNET, and reveal which amino acid residues are responsible for the binding of inhibitors. In this
study, we built spatial NET models, docked selected inhibitors into the binding pocket, and evaluated
ligand-receptor interactions.
2. Results and Discussion
2.1. Model Building and Evaluation
To provide structural information for NET, we constructed three-dimensional models built with
amino acid sequence of a human norepinephrine transporter on the basis of templates from related
homologous proteins. Of all the members of the SLC6 family, human DAT shows the greatest homology
to NET with an amino acid sequence identity of 78%. Moreover, both reveal transport of mutual
substrates [16].
Differences and similarities between human MATs were examined after alignment of protein
sequences and their spatial structures. Alignment of sequences was carried out on the PROMALS3D
web server [27]. We used sequences of human NET, DAT, and SERT. Primary sequences of mammalian
equivalents are strikingly identical, yet their selectivity for substrates and inhibitors included different
structural determinants [11,16]. This comparison revealed good alignment of almost all amino acid
residues and a high conservation index (Figure 1) [28]. The sequence used for the generation of hNET
models represented a deletion of amino acid residues from the polypeptide chain at N- and C-termini.
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Residues between A73 and L76 (TM1) and the longer part at TM6 between L319 and L326 were
determined hinge regions which possess an unfolded structure.Biomolecules 2019, 9, x FOR PEER REVIEW 4 of 20 
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models. The similarity in sequence between dDAT and human NET reached the level of 63.3%; also, 
the sequence identity was considerable (49.6%) [30].⁠ Both of the dDAT represented outward-open 
conformation with a bound cocaine analog and nortriptyline in the central binding site of 4xpg and 
4m48 crystal structures, respectively. Inhibitors blocked the transporters from binding with substrate, 
preventing further conformational changes toward occluded and inward-open state [9,31]. 
The homology modeling was carried out on a SWISS-MODEL server [32]. The hNET models 
were constructed automatically through target-template sequence alignment. Based on the quality 
assessment, the four top-ranked models were chosen. We took into consideration relevant quality 
estimations, such as global model quality estimation (GMQE), qualitative model energy analysis 
(QMEAN), and others (Figure 2). 
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The GMQE score estimated the quality of each model with different properties resulting from 
target-template alignment and the method of searching for a template. The score which we obtained 
rated the represented models with high reliability and accuracy, with values close to 1 rather than 0. 
Qualitative model energy analysis applied the statistical potential in cases of the comparison of tested 
models to the experimental structures available in the SWISS-MODEL server database. The QMEAN 
Z-score parameters evaluated the grade of nativeness of the structural model data on a global scale. 
QMEAN4 values, which were in closer relation to 0, characterized good agreement of the generated 
model structures with similar sized experimental structures [33]. All of the results generated for 
models 1–4 represented a similar range of values from −3.85 to −3.82. In consideration of the obtained 
results, we used two top-rated and structurally the most different hNET models for further 
evaluation and docking studies (Figure 3A,B). 
Figure 1. Representation of fragment of sequence alignment for core domains and extracellular loop
EL4 of human NET, DAT, and SERT. The most important residues found at hNET models involved in
binding ligands are marked in blue. First line depicted as red represented the alpha-helix secondary
structure predicted by PROMALS3D [29].
To create the NET structure we used two of the Drosophila melanogaster dopamine transporters
(dDAT)—Protein Data Bank (PDB) codes: 4xpg and 4m48—as te plates. These two were proposed
by a homology-modeling server, which assigned them the highest score, providing further top-rated
models. The similarity in sequence between dDAT and human NET reached the level of 63.3%; also,
the sequence identity was considerable (49.6%) [30]. Both of the dDAT represented outward-open
conformation with a bound cocaine analog and nortriptyline in the central binding site of 4xpg and
4m48 crystal structures, respectively. Inhibitors blocked the transporters from binding with substrate,
preventing further conformational changes toward occluded and inward-open state [9,31].
The homology modeling was carried out on a SWISS-MODEL server [32]. The hNET models
were constructed automatically through target-template sequence alignment. Based on the quality
assessment, the four top-ranked models were chosen. We took into consideration relevant quality
estimations, such as global model quality estimation (GMQE), qualitative model energy analysis
(QMEAN), and others (Figure 2).
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The spatial structure of SCL6 transporters was based on a helical 5 + 5 scheme, where TM1–5 and
TM6–10 formed two antiparallel pentahelical clusters aligned to one another. The type of symmetry
was a representation of a pseudo two-fold axis arrangement [14]. Based on superposition, it could be
ascertained that two selected models were very similar. Small differences between both hNET models
could be found in the spatial arrangement of extracellular loops. (Figure 4A). After visualization of the
transporter surfaces, a small crevice which led from the external to the interior environments, could
be identified (Figure 4B). That fissure provided a pathway by which the hydration of the active site
ensued and substrates or inhibitors could reach the high affinity binding pocket.
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Figure 4. The hNET model presentation: (A) Superposition of two selected models. Comparison of the
whole proteins. Model built on 4xpg template is shown as yellow, while on 4m48 as blue. Sodium ions
are indicated in purple, chloride ions in green. (B) Surface of the model built on 4xpg template structure.
By visualization of the area occupied by amino acid residues, an access gate to the internal part of
the transporter could be easily detected. Surface of core domains and EL4 have been colored in red
for contrast. Proposed entry pathway from extracellular site for NET inhibitors are indicated by
white arrow. (C) Representation of model built on 4m48 structure both as surface and cartoon in blue.
Core domains and EL4 are marked in black.
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Despite the transient nature of interaction between the external entry pathway and the transported
molecule, composition of this extracellular part favored selectivity of NET inhibitors. This assumption
was further confirmed by the reported loss of uptake and binding ability, as a consequence of single
DAT residue introduction into EL4. As a gatekeeping part, EL4 was highlighted as the first element in
recognition of inhibitors and selectivity by the transporter. However, compared to the high affinity
binding site (S1), EL4 played only a minor role in substrate recognition [34]. Built models of hNET were
consistent with the literature data about monoamine transporters. Superimposition of the transporter
core: TM1 and TM3 the bundle and TM6 and TM8 the scaffold domains, together with EL4, which
is divided into two subunits (A and B) provided information about general structure of the hNET
models. Core domains represented similar configuration. Some distinction could be observed in terms
of the connection of subunits of TM6 and the placement in active sites of ions. Also, EL4 differed in its
observed secondary structures found at the part of the sequence included at subunit 4a. Glutamic acid
E377 and aspartic acid D378 residues presented different conformations. In the 4m48-based model,
this fragment was represented as an alpha-helix, while in the 4xpg-based model it created a disordered
secondary structure (Figure 5A).
MATs and amino acid transporters were thought to have a secondary binding site (S2), located
closer to the extracellular region between EL4 and S1, which was thought to have lower affinity in
binding molecules [13]. That additional binding pocket was functionally responsible for allosterically
triggering conformational changes from occluded state to inward-facing, and thereby release of
ions and associated molecule. This feature occurred as a result of hydration of the primary site [13].
At 4xpg and 4m48, hNET models entry pathway was formed by transmembrane domains TM1, TM3,
TM6, TM10, TM11, and extracellular loops EL4 and EL6. Amino acid residues localized in these
components of the transporter may take part in binding molecules before they reach S1 site. Such an
assumption was confirmed by computational methods with NET models built on LeuT matrix [35].
In the prokaryotic homolog LeuT, precise structural features involved in coupling substrates at site S2
were nondetermined. Despite the lack of information about the exact molecular determinants, several
X-ray crystal structures of LeuT presented occupancy by some tricyclic antidepressants (TCAs) and
selective serotonin reuptake inhibitors (SSRIs) in this site [22,36]. These findings were supported by
experimental data showing an impact of mutations within S1 and S2 on recognition of certain inhibitors
by the protein [14]. Changes of a few residues located in the S2 region mostly entailed reduction in
the affinity and potency of several inhibitors [37]. Moreover, the halogen binding pocket which has
been reported to occur between S1 and S2 was particularly reliable for determining specificity [38].
Other strong evidence of the importance of the vestibular binding site was supported by the fact that
binding of the substrate molecule to S2 in the LeuT crystal structure triggered release (in this case of
leucine) to the cytoplasm from S1 [37]. Based on molecular dynamics stimulations and mutagenesis
studies, the most important residues at the hDAT were detected. First, aspartic acid D79 (corresponding
D75 at hNET) residue was indicated, in view of both substrates and inhibitors amine group recognition.
The second residue to be indicated was aspartic acid D476 (D473 hNET) as it interacts with hydroxyl
moieties [39]. Moreover, studies, carried out on mutated dDAT containing nonconserved hNET and
hDAT residues within the substrate/inhibitor pathway to the intracellular space, supported the idea
that these residues control selectivity at hNET but not at hDAT. As key determinants, amino acids
within S1 were indicated [34]. Due to the lack of clear demarcation between vestibular and primary
binding pocket several residues belonged to both S1 and S2. This statement could be confirmed by the
fact that two binding sites overlapped also at hSERT [40]. At 4xpg and 4m48, hNET models centrally
localized tyrosine Y151 and Y152 could be equally a component both of S2 and S1. As a nonconserved,
residues should be highlighted tyrosine Y151 from TM3, threonine T381, glutamic acid E382, alanine
A384 and valine V387 from EL4, and leucine L469 and threonine T474 from TM10 at the putative
secondary binding site (Figure 5D). At the primary binding site, nonconserved amino acids were
alanine A145 and tyrosine Y151 from TM3, isoleucine I315 and phenylalanine F316 from TM6, and
serine S420 and alanine A426 localized at TM8 (Figure 5E).
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The primary binding site in our hNET transporter models appeared approximately midway across
the membrane bilayer and for 4xpg hNET model presented occupancy by a small molecule: methyl
(1R,2S,3S,5S)-3-(4-fluorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate. The compound was
inherited from the dDAT template (4xpg). The aforementioned cocaine derivative was active against
MATs including hNET with the value Ki = 635 nM (pKi = 6.2) [41]. The compositions of binding pockets
in hNET were responsible for high selectivity and affinity in ligand recognition [34]. For assessment of
possible interaction between retained cocaine analog and models, we conducted superimposition of
protein binding pockets and identified available contacts within 5.5 Å of the ligand (Figure 6). If we
took into consideration the physicochemical character of amino acid residues arranged at the centrally
located binding region, they could be divided into different segments. The binding pocket consisted
of a hydrophobic region responsible for coordination of aromatic rings and a hydrophilic site where
the aspartic acid D75 residue was situated. The hydrophobic site included residues of alanine A145,
valine V148, glycine G149, and tyrosine Y151 and Y152 from TM3, serine S419 and S420, glycine G423,
methionine M424 from TM8, and glycine G320 and phenylalanine F323 from TM6. The farther located
residues were aspartic acid D473, alanine 477, and isoleucine from TM10. On the other hand, the
hydrophilic site consisted of phenylalanine F72 and aspartic acid D75 from TM1 and phenylalanine
F317, and serine S318 from TM6. Situated above 4 Å, were valine V74, alanine A77 from TM1 and
phenylalanine F316, leucine L319, and valine V325 from TM6. The importance of aspartate 75 residue
in forming polar contacts should be emphasized. Mutation studies revealed that replacement of this
residue with alanine, glycine, or arginine caused a loss of transport ability [12]. Measurements of
distance between nitrogen atom from the azabicyclooctane ring and oxygen atoms from side chain
carboxyl of D75 revealed a close arrangement of 3.2 Å in 4xpg model, while in 4m48 model the distance
was 0.5 Å longer. Other residues which could be involved in creating bonds were tyrosine Y151 and
Y152 phenyl rings seizing the ligand molecule from the external part of TM3. Phenylalanine F72 and
F317 provide binding from the opposite site. F323 residue from TM6 was spatially differently arranged
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and that fact may have an impact on forming interaction with ligands. Aromatic moieties of F323 were
located 3.4 Å apart from each other, measured from the center of rings. The inherence of identified
amino acid residues overlapped with several so far created experimental mutants of homologous
proteins containing the amino acid sequence of hNET at the binding site [20,42]. Comparison between
hNET models and their dDAT templates revealed small differences. At 4xpg model, the hNET side
chain carboxyl group D75 (D46 at dDAT) was pointed toward center of the binding pocket, while the
Drosophila DAT one was bent closer to the Na+1 ion with a shift of 0.8 Å. At 4m48, the hNET model and
4m48 X-ray dDAT, this difference was half the size (0.4 Å). The composition of residues within direct
range of 4 Å from ligands also differed a little. At dDAT crystal structure (4xpg) with a cocaine analog,
a second tyrosine Y123 (Y151 at hNET model) residue from TM3 could be observed. The 4m48 hNET
model superimposed to 4m48 dDAT with TCA presented additional glycine G149, serine S420, and
alanine A477. All of the mentioned residues could be located at both hNET models but had different
impact in binding of molecules. G149 (at hNET) was nonconserved in the eukaryotic dDAT homolog,
and D121 takes its place.
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The importance of the results could be supported by a superimposition with another X-ray protein
structure which was designed to reflect a biogenic amine transporter: Modified leucine transporter
(LeuBAT) from PDB encoded, 4mmd and 4mme (Figure 7). LeuBAT has been constructed as a mutant
of wild-type prokaryotic homolog LeuT to provide structural features and pharmacological properties
as a hybrid of human BATs. Amino acid residues within active site S1 of LeuT were replaced by the
ones from the hSERT sequence. Transporters were isolated from Aquifex aeolicus and represented
a complex with (S)-duloxetine (4m d) and mazindol (4mme) molecules. The LeuBAT binding site
was divided into specific subsites. Comparison of the LeuBAT binding pocket with the one of the
received hNET models may provide subsequent inferences regarding any impact exerted on interaction
ith ligands. Subsite A formed by residues from TM1, 6, and 8 contained sites where ions bind.
Situated at TM1b, D24 was reported to bind co pounds by a salt bridge and this correspon ed to
one in hNET which was also a residue of aspartic aci (D75). Side chain carboxyl group was directed
toward the intracellular part of the pocket, while the same atom from D24 (4mmd) was pointed in an
external direction to TM1b. T e distance measured between carboxyl groups was 3.0 Å. The rest of
the corresponding ami o acid residues at subsite A possessed a hydrophilic character (from a region
closer to TM8) or hydrophobic (at the opposite irection: Phenylalanine F317 and F323, glycine G320).
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The composition of distal located subsite B presented a sizable niche constructed by nonpolar residues.
All of these presented an arrangement of the side chains directed to the interior of the binding pocket.
Here, we imply that residues valine V148 and glycine G149 should be identified as initial structural
determinants amenable to binding of the compounds in hNET. However, the LeuBAT transporter
possessed high affinity only in binding the compounds. Transport activity was not observed and this
may affect the reliability of the results [43].
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In the hNET models built on matrixes 4xpg and 4m48, we observed one chloride and two
sodium ion binding sites within 8.0 Å of the ligand inherited from 4xpg dDAT template (methyl
(1R,2S,3S,5S)-3-(4-fluorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate) at regions of TM1,
TM6, and TM8 (Figure 8). Two Na+ ions were situated at a distance of 7.2 Å and 7.8 Å from each other
in 4m48 and 4xpg hNET models, respectively. A chloride ion was found to be the farthest from the
ligand in the region of TM6a. Measured distances between chloride and sodium ions were 5 Å (4m48
hNET) and 5.4 Å (4xpg hNET) from central Na1 and 11.8 Å (4m48 hNET) and 12.6 Å (4xpg hNET)
from peripheral Na2. To define residues at the binding sites, we analyzed amino acids located 5.5 Å
away from each ion. In 4xpg model, the Na1 site consisted of alanine A73, aspartic acid D75, and
asparagine N78 residues from TM1b; serine S318 from TM6a; and asparagine N350 from TM7. Na+ was
coordinated with similar to octahedral geometry derived from the main chain carbonyl oxygen atoms
and side chain oxygens. In the 4m48 model, D75 could participate in Na+ coordination by a side chain
carbonyl oxygen atom which differed from the sodium binding presented at the 4xpg hNET model.
In this case, the sodium ion also had a common octahedral coordination geometry, as was observed
for prokaryotic homologs [10,39]. At the greater distance within the Na1 site (over 4 Å) valine V74,
alanine A77, phenylalanine F317, and leucine L319 residues were situated in both of the hNET models.
The Na2 site located closer to TM8 showing trigonal bipyramidal geometry was created through the
main chain oxygen atoms of glycine G71 (TM1a), valine V74 from the TM1 hinge region loop, leucine
L415 from TM8, and side chains of aspartic acid D418 and serine S419 from TM8 in both hNET odels.
Oxygen atoms from D75 did not participate in sodium coordination due to their measured distances of
over 5.5 Å from the Na+2 ion. Other residues within a radius of 5.5 Å were phenylalanine F72, alanine
A73, tyrosine Y152, alanine A414, glycine G416, leucine L417, serine S420 at the 4xpg hNET model,
and additional valine V70 at the 4m48 hNET model with the lack of serine S420. The anion binding
site contained S318 residue also present at the Na1 site, and which was able to interact with both ions
by a hydroxyl group. Tetragonal pyramidal coordination of the Cl− was possible due to interplay
with oxygen from tyrosine Y98 (TM2), nitrogen atoms from glutamine Q314 (TM6), asparagine N350
amide nitrogen atom, and serine S354 located at the TM7 region. The main chain amide nitrogen atom
from phenylalanine F82 was not involved in coupling the Cl− ion, because of the too-large distance
separating them in the 4m48 hNET structure. Residues located adjacent to Cl−, which did not directly
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coordinate the chloride anion, are asparagine N78, phenylalanine F82, isoleucine I315, and cysteine
C351 at the 4xpg hNET model, and alanine A77, asparagine N78, and cysteine C351 at the 4m48 hNET
model. The measured distance between the Na+2 and Cl− ions was located at the extreme distance to
12.6 Å in 4xpg and 11.8 Å in the 4m48 hNET models.
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General differences in the composition of ion binding sites between the LeuT amino acid transporter
and MATs were directly related to ion dependencies. Substitution of Glu290 in LeuT for serine in
MATs at the chloride binding region induced a Cl− dependent transport cycle [23]. Residues of amino
acids located at the active site were highly conserved in MATs. Received outcomes presented identical
amino acid compositions responsible for the ion binding scheme in hNET models corresponding to
experimental data (Table 1) [44].
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Table 1. Summary of residues involved in ion binding represented for LeuT, monoamine transporters,
and hNET 4xpg and 4m48 models. Primary differences in properties in amino acid residues are
presented in bold letters.
Ion aLeuT (2qju) hDAT [23] dDAT (4m48) hNET [23] hNET Models 4xpg and 4m48
Na+1
leucine (substrate) Asp79 Asp46 via H2O Asp75 Asp75
Ala22 Ala77 Ala44 Ala73 Ala73
Asn27 Asn82 Asn49 Asn78 Asn78
Thr254 Ser321 Ser320 Ser318 Ser318
Asn286 Asn353 Asn352 Asn350 Asn350
Na+2
Gly20 Gly75 Gly42 Gly71 Gly71
Val23 Val78 Val45 Val74 Val74
Ala351 Leu418 Leu417 Leu415 Leu415
Thr354 Asp421 Asp420 Asp418 Asp418
Ser355 Ser422 Ser421 Ser419 Ser419
Cl−
Lys121 Tyr102 Tyr69 Tyr98 Tyr98
Ser150 Ser321 Ser320 Ser318 Ser318
Tyr151 Asn353 Asn352 Asn350 Asn350
Ser165 Gln317 Gln316 Gln314 Gln314
Phe167 Ser357 Ser356 Ser354 Ser354
2.2. Norepinephrine Transporter Inhibitors
From various well-known norepinephrine reuptake inhibitors, 9 have been chosen based on their
affinity to human NET and selectivity (Figure 9). The 10th additional compound was a piperidine-based
hybrid of nocaine and modafinil as a highly potent MATs inhibitor, referred to subsequently in this
paper as “compound X”: 2-({[4-(4-chlorophenyl)-1-methyl-3-piperidinyl]methyl}sulfinyl)ethanol [45].
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Fig re 9. Values of pKi (negative logarithm of the dissociation constant of ligand—transporter complex)
of selected monoamine transporter inhibitors; pKi have been measured for human MATs. Exceptions are
modafinil and compound X whose affinity has been appointed for Rattus norvegicus equivalent. All of
the values were taken from the ChEMBL Database [46].
All of the selected inhibitors may be useful in the treatment of a number of central nervous system
(CNS) diseases in which dysfunction of the noradrenergic system is involved. Of the thymoleptic
drugs which represent the effect via NET, the following pharmacological classes may be distinguished:
tricyclic antidepressants (TCAs), norepinephrine reuptake inhibitors (NRIs), norepinephrine/dopamine
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reuptake inhibitors (NDRIs), and serotonin/norepinephrine reuptake inhibitors (SNRIs). Stimulation of
CNS caused by mazindol, modafinil, and nocaine was reported as a result of NET/DAT inhibition.
Mazindol suppresses appetite; therefore, it has been used in the short-term treatment of adiposity.
Modafinil exerts wake-promoting activity and thus is prescribed in sleep disorders such as insomnia
or hypersomnia. The last one, nocaine, was developed as a substitute agent for cocaine and tested for
treatment of addiction in clinical trials [6]. Compound X has been developed as a hybrid of nocaine and
modafinil molecules to improve potency toward MATs, but especially for NET and DAT inhibition [45].
Selected compounds presented high diversity in the chemical structures (Figure 10).
Both desipramine and nortriptyline share similar tricyclic structures with coplanar architecture.
On the other hand, mazindol’s tricyclic ring system built with isoindole and imidazole represents
a flat arrangement. The remaining structures contain several separate aromatic and/or heterocyclic
rings, or only one, like in bupropion. However, most importantly, they represent the same motif
responsible for binding to monoamine transporters (MATs). The relationship between structure and
exerted activity has been thoroughly studied and reported elsewhere. Here, it should be mentioned
that aromatic residues in close relation to each other and basic amino groups are located 3 to 5 atoms
away [47]. Higher affinity to NET was observed for secondary amines, while tertiary ones were more
selective for SERT. The type of substitution on the phenyl ring also played a significant role in affinity
and selectivity. The presence of an electron withdrawing group (like halogen, haloalkyl, sulfonyl group)
affects the extended activity profile also toward SERT or DAT inhibition [47,48]. The substitution of
the halogen atom and additional groups at the phenoxy ring are known to be key features that make
NRIs specific to NET versus those that make other inhibitors specific to the rest of the monoamine
transporters. Single substitution at the second position by a methyl (-CH3) or methoxyl group (-OCH3)
yields norepinephrine specific inhibitors such as reboxetine. Unlike the presence of one or both halogen,
methyl or methoxyl groups at the fourth position are responsible for specificity toward SERT [39].
That specific structural insight may have an impact on the recognition of these drugs by NE transporters
and placement of the molecules in the binding pocket.
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2.3. Docking Studies
All of the selected compounds were docked into the binding pocket of selected NET models.
Calculated docking scores show that duloxetine, mazindol, nocaine, and compound X fit better to the
model built on the 4xpg dDAT template, while the others are better fitted into the 4m48 hNET model
(Table 2).
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Table 2. Docking GlideScore of selected compounds for hNET models on dDAT templates 4xpg
and 4m48.
Compound hNET Model 4xpg hNET Model 4m48
Desipramine −7.602 −9.225
Nortriptyline −7.137 −9.432
Reboxetine −7.071 −8.158
Bupropion −6.584 −6.859
Duloxetine −7.859 −7.295
Mazindol −8.845 −8.624
Modafinil −7.793 −8.177
Nocaine −7.392 −7.269
Venlafaxine −7.603 −7.674
Compound X −8.530 −7.620
The values in bold indicate the model which resulted in a better binding mode of ligand and provided more
beneficial value of scoring function.
Residues involved in binding were determined and results were confirmed by comparison with
literature data [2]. In the 4xpg and 4m48 models of hNET, five residues were involved in creating
interactions with compounds: Internally located phenylalanine F72 from TM1b, aspartic acid D75
at the opposite direction from TM1a, tyrosine Y152 from TM3, and phenylalanine F317, F323 from
cytoplasmic subunit of TM6. The binding mode of hNET inhibitors could generally be defined by the
ionic bond derived from side chain oxygen atoms of D75 and protonated amine moiety of ligands,
conformationally different types of π-π stacking created between phenyl rings of Y152, F323, and
aromatic residues of each compound. Additional interactions are provided by carboxyl oxygens from
F72 and F317 by H-bonds or π-cations derived from the aromatic ring of F72 with protonated amine
moieties in NET inhibitors. Aromatic moieties of docked inhibitors are surrounded by hydrophobic
residues located closer to the secondary binding site.
TCAs presented the same arrangement of the tricyclic moiety in the active site of the NE transporter.
Both aromatic rings form parallel-displaced π stacking with Y152 and F323 with a bond length of 4.6 Å
for desipramine and 4.6–4.7 Å for nortriptyline and remain in close contact with valine V148 which
is important in recognition at hNET. The basic amino nitrogen atom is coordinated by main chain
carbonyl oxygen atoms from residues F72, F317, and also with serine S318 by H-bonds. Change of
the nitrogen at the tricyclic ring system into a carbon atom with sp2 configuration in the nortriptyline
molecule has an impact on placement of the propylamine chain. In this case, the salt bridge formed with
D75 is shorter in length and would be stronger than that observed for desipramine. The protonated
nitrogen atom could be coordinated by a π-cation from F72 with a bond length of 4.3 Å for nortriptyline
and 3.9 Å for desipramine (Figure 11).
Binding of selective inhibitor reboxetine to the S1 site has been proposed as the coordination of an
amine group from the heterocyclic morpholine ring with D75 by a strong ionic bond with a length of
3.6 Å and in addition also with residues of F72, F317, and S318. The lengths of the H-bonds formed by
residues from subunit TM6b are likewise shorter for this inhibitor molecule which could elucidate
the selectivity of inhibition by that drug to hNET. Only one phenyl ring could be stabilized in the
active pocket by T-shape π-π interaction derived from Y152. A second aromatic reboxetine moiety is
separated by a greater distance from Y152 (5.8 Å) and F323 (6.0 Å) (Figure 12A).
The modafinil molecule could interact via a nitrogen atom from the amide with the F72 side chain
aromatic ring. Typical ionic bond with D75 is not detected due to the presence of amide nitrogen
non-ionized in physiological pH. Except for the mentioned difference, modafinil is typically kept in
the binding site by hydrophobic residues from TM3 and also forms H-bonds with main chain oxygen
atoms from F72 (162.6◦) and F317 (162.5◦) (Figure 12B).
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Compounds substituted by a halogen atom at the aromatic ring represent insertion of a chloride
atom into the niche where hydrophobic residues are located (Figure 13). For bupropion, halogen
bond could be derived from the main chain oxygen atom from glycine G423 (4.7 Å) and F323 (4.4 Å).
Chlorine moiety from nocaine is bound by G423 and by additional interaction with V148 and alanine
A145. Docking of bupropion molecules presents polar contacts with D75. Another interaction is
created by F72 aromatic residue which bound to the inhibitor’s amino group by π-cation. The π-π
stacking p ovided from F323 is observ d here in a T-shape position. Detection for nocaine T-shaped
π-π stacking is provided by both aromatic rings from exterior and i terior sides. The basic nitrogen
atom from the piperidine ring of compound X remained in closed arrangement to D75 with by far
the strongest salt bridge of all of the halogen substituted agents. A hydroxyl group penetrated to the
exterior side of the pocket and created an H-bond (2.7 Å, 163.4◦) with a side chain carbonyl from D473
located at TM10. Aromatic rings are typically bound with Y152 and F323 which are close to T-shape
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position of π-stacking. Oxygen from a sulfinyl group could also be coordinated by an H-bond derived
from a phenyl group of Y151 (2.9 Å, 137◦). Protonated amine moieties from all these three compounds
could not be stabilized by π-cations of aromatic F72 rings due to the extreme distances between them.
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4mmd as pink. Duloxetine and mazindol molecules docked to hNET are presented as light gray sticks,
while inhibitors crystallized with LeuBAT are dark gray lines. The most important residues involved in
binding drug molecules are presented as sticks. Measured distances between particular functional
groups and docked compounds in 4xpg hNET are shown as orange dashed lines, while in 4mme and
4mmd they are omitted for clarity. Sodium ions are shown as purple spheres, chloride ions as green for
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To summarize the spatial arrangement of docked inhibitors at the primary binding region, several
important observations should be noted. Firstly, the nitrogen atom from the amine moiety remains in
close contact with residues of phenylalanine F72, aspartic acid D75 from core domain 1, and amino
acids from TM6-phenylalanine F317 and serine S318. All docked inhibitors are bound by protonated
amine moieties to D75 with ionic bond, with one exception of modafinil. Aromatic rings are stabilized
by hydrophobic π-π stacking derived from tyrosine Y152 (TM3) and phenylalanine F323 (TM6) from the
opposite side of the binding pocket. Aromatic moieties are surrounded by hydrophobic residues which
are responsible for recognition of these ligands by hNET like the mentioned valine V148. The presented
results constitute an extension of the published data [23,34] as we focused on many aspects of hNET,
including the analysis of greater amount of inhibitors.
3. Materials and Methods
3.1. Sequences and Homology Models
For the study, the amino acid sequence of the human norepinephrine transporter (UniProt ID
P23975) was downloaded. As templates to onstruct all the homology mod ls, we used X-ray c ystal
structures of pamine transporters from Drosophila melanogaster PDB IDs: 4xpg [49] and 4m48 [50],
with resolutions 3.21 Å and 2.96 Å, respectively. The three-dim nsional hNET structures were built
us ng the SWISS-MODEL server [51]. Generated 4xpg and 4m48-based hNET models contained two
sodium and one chloride ions inherited from dDAT templates. The 4xpg h ET als included a cocaine
analog located at t e b nding pock t n X-ray 4xpg dDAT. All the pr sented models were selected
according to knowledge-bas d QMEAN and GMQE values [33]. For multiple quence alignment
hNET (UniProt ID P23975), hDAT (UniProt ID Q01959), and hSERT (UniProt ID P31645) sequences wer
used. The process was carried out on t e PROMALS3D multiple sequence and structure alignment
rver [27].
3.2. Ligands Preparation
All of the presented inhibitors were selected according to affinity and selectivity determined
experimentally toward hNET and Rattus norvegicus rNET, taken from the ChEMBL database of
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bioactive molecules [42]. Ligands were prepared in the MAESTRO program using the Schrödinger
LigPrep calculation package. The procedure involved taking into account ionization occurring at
physiological pH (7.4 ± 0.2) with an availed OPLS_2005 (Optimized Potentials for Liquid Simulations)
force field. Absolute configuration was determined for all the asymmetric carbon atoms. To obtain
reliable results, the appropriate stereoisomers corresponding to those used with registered/inspected
drugs were selected.
3.3. Docking
The first step involved default preparation of models in the Protein Preparation Wizard. For 4xpg
hNET (x = 40.267, y = −1.411, z = −25.393) and 4m48 hNET (−40.899, 1.143, 57.732) grid centers were
adopted with an inner box size of x = 22 Å, y = 22 Å, z = 22 Å, for both of them. The centers of binding
sites were defined by residues F72, D75, Y151, Y152, F323, and D473 for 4xpg and 4m48 hNET models.
The second step involved glide docking of selected compounds and was performed using a standard
procedure with all the default settings. At both stages, an OPLS_2005 force field was applied.
4. Conclusions
To conclude, the constructed models of human norepinephrine transporter provide a good reference
point for suggestions as to how the atomic structure of this protein might look. Meticulous examination
of the spatial arrangement of initial elements engaged in ligand recognition from the entry pathway to
high affinity binding sites allows for elucidation of the selectivity and placement of bioactive molecules.
Models built on 4xpg and 4m48 dDAT templates possess a different spatial arrangement of hydrophobic
phenylalanine F323 residues, which is important in catching aryl moieties from intracellular space.
Several compounds may interact with residues not conserved, i.e., tyrosine Y151 and serine S423.
Other findings showed the close relationship of the halogen atom with valine V148, experimentally
proven as also being important in hNET ligand recognition. We hope that the presented data analysis
may have an impact on understanding the molecular interactions between norepinephrine transporter
and its inhibitors and have an impact on future development of novel bioactive compounds.
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Abbreviations
5-HT 5-hydroxytryptamine, serotonin
ADHD attention deficit hyperactivity disorder
BAT Biogenic amine transporter
cDNA Complementary DNA
CNS Central nervous system
DAT Dopamine transporter
dDAT Drosophila dopamine transporter
EL2 Extracellular loop 2
EL4 Extracellular loop 4
GMQE Global Model Quality Estimation
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hDAT Human dopamine transporter
hNET Human norepinephrine transporter
IL1 Intracellular loop 1
LeuBAT Leucine biogenic amine transporter
LeuT Leucine transporter
MAT Monoamine transporter
NDRIs Norepinephrine/dopamine re-uptake inhibitors
NE Norepinephrine
NET Norepinephrine transporter
NRIs Norepinephrine re-uptake inhibitors
NSSs Neurotransmitter sodium symporters
PDB Protein Data Bank
pKi Negative logarithm of the dissociation constant of ligand—transporter complex
QMEAN Qualitative Model Energy Analysis
SERT Serotonin transporter
SLC6 Solute carrier family 6
SNRIs Serotonin/norepinephrine re-uptake inhibitors
SSRIs Selective serotonin re-uptake inhibitors
TCAs Tricyclic antidepressants
TM Transmembrane domain
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